|
|
|
|
|
Highlights from the 2022 American Urological Association Annual Meeting (AUA) |
|
|
|
|
| Bladder Cancer: Upper Tract Transitional Cell Carcinoma II |
| Antegrade Administration of Reverse Thermal Mitomycin Gel for Primary Chemoablation of Upper Tract Urothelial Carcinoma via Percutaneous Nephrostomy Tube: a Multi-Institutional Real-World Experience
|
| Kyle Rose, MD, MS
|
| The 2022 Annual Meeting of the American Urological Association was host to a podium presentation by Dr. Kyle Rose from Moffitt Cancer Center who presented real-world data on the antegrade administration of reverse thermal mitomycin (JEMLYTO®) for primary chemoablation of upper tract urothelial carcinoma (UTUC) via a percutaneous nephrostomy tube.
|
|
|
|
|
|
| Prostate Cancer: Advanced (Including Drug Therapy) II |
| Chemoablation as Primary Treatment: Transforming the Paradigm for Low Grade UTUC with JELMYTO®
|
| Jennifer A. Linehan, MD
|
| The 2022 Annual Meeting of the American Urological Association was host to an exhibition hosted by UroGen® and presented by Jennifer Linehan. Dr. Linehan began her presentation by highlighting that the long-term standard of care has delivered suboptimal outcomes for low-grade upper tract urothelial cancer (LG-UTUC) patients.
|
|
|
|
|
|
| Society of Urologic Oncology (SUO) |
| Adjuvant Therapy after Nephroureterectomy for High-Risk Upper Tract Urothelial Carcinoma |
| Sima Porten, MD, MPH |
| Sima Porten discussed adjuvant therapy after nephroureterectomy for high-risk upper tract urothelial carcinoma. Patients at high risk of recurrence after definitive surgical treatment for upper tract urothelial carcinoma should be referred for consideration of adjuvant therapy, including patients with (i) high grade pT2-pT4 and/or pN+ disease, and (ii) if neoadjuvant chemotherapy was given, ypT3-4a and/or ypN+ disease. There is level 1 evidence for adjuvant chemotherapy (gemcitabine + platinum). |
|
|
|
|
|
| Rescue Therapy and BCG Alternatives in NMIBC
|
| Max Kates, MD
|
| Max Kates discussing rescue therapy and BCG alternatives in non-muscle invasive bladder cancer (NMIBC). Dr. Kates started his presentation by noting that the United States now has one supplier of BCG, with three major shortages in the past decade. The implications of these BCG shortages have been assessed in previous studies, reporting that there are significant differences in recurrence free survival among patients treated during the BCG shortage compared to patients treated during times of normal supply.
|
|
|
|
|
|
| Late-Breaking Abstract I |
| Interim Results From a Phase 1B Clinical Trial Evaluating Tolerability and Activity of FGFR Inhibition in Localized Upper Tract Urothelial Carcinoma |
| Surena Matin, MD |
| In a podium presentation in the Late-Breaking Abstracts session at the 2022 American Urologic Association Annual Meeting held in New Orleans and virtually, Surena Matin presented the results of a phase Ib trial assessing the tolerability and activity of FGFR inhibition in patients with localized upper tract urothelial carcinoma (UTUC). |
|
|
|
|
|
| Plenary |
| Final Clinical Results of Pivotal Trial of IL-15R&[alpha]Fc Superagonist N-803 with BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) CIS and Papillary Cohorts
|
| Karim Chamie, MD
|
| In a podium presentation at the 2022 American Urologic Association Annual Meeting held in New Orleans and virtually, Dr. Chamie presented the results of N-803 in combination with BCG in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
|
|
|
|
|
|
|
|
|
|
|
| Bladder Cancer: Epidemiology & Evaluation I |
| Long-term Follow-up of Intravesical Gemcitabine and Docetaxel as Rescue Therapy for NMIBC
|
| Michael A. O’Donnell, MD
|
| Michael O’Donnell discussing long-term follow-up of intravesical gemcitabine and docetaxel as rescue therapy for non-muscle invasive bladder cancer (NMIBC). While radical cystectomy remains the preferred treatment for bacillus Calmette-Guérin (BCG) unresponsive high-risk NMIBC, many patients are either unwilling or unfit to undergo surgery. Previous retrospective studies have demonstrated the efficacy of intravesical gemcitabine and docetaxel for treating NMIBC after BCG failure but only reported moderate-length follow-up.
|
|
|
|
|
|
| Bladder Cancer: Non-invasive I |
| A Randomized Study to Compare Outcomes of Intravesical Chemohyperthermia with Mitomycin C Versus Intravesical BCG for Intermediate and High Risk NMIBC |
| Karandeep Guleria, MD, MS |
| Karandeep Guleria discussed a randomized study assessing intravesical chemohyperthermia with Mitomycin C versus intravesical BCG for intermediate and high risk non-muscle invasive bladder cancer (NMIBC). Based on these results, chemohyperthermia is an alternative option to intravesical BCG therapy as adjuvant treatment for intermediate and high-risk NMIBC. |
|
|
|
|
|
|
|
|
|
|
STATE-OF-THE-INDUSTRY VIDEOS BY LEADING UROLOGY EXPERTS
|
|
|
|
|
|
| How I Treat Low-Risk Upper Tract Urothelial Carcinoma
|
| Katie S. Murray, DO, MS, FACS
|
| Sam Chang is joined by Katie Murray to discuss treatment options for low-grade upper-tract disease. As the treatment for this disease has evolved over time, Dr. Murray focuses her presentation on her practice and the nuts and bolts of how she treats upper tract urothelial carcinoma.
|
|
|
|
|
|
|
|
|
|
|
|
| Management and Challenges of Low Grade Upper Tract Urothelial Carcinoma |
| Surena F. Matin, MD |
| In this patient case evaluation discussion, Surena Matin joins Sam Chang presenting a patient case of low grade, upper tract, urothelial cancer. Drs. Matin and Chang discuss diagnosing and staging the patient, and Dr. Matin talks through his approach to treatment. |
|
|
|
|
|
|
|
|
|
|
|
| Long-Term Safety and Durability to Non-Surgical Treatment Instillation of UGN-101, Mitomycin-Containing Reverse Thermal Gel for Low-Grade Upper Tract Urothelial Carcinoma, Journal Club |
Zachary Klaassen, MD, MSc and Chris Wallis, MD, Ph.D.
In this UroToday Journal Club video presentation, Christopher Wallis and Zachary Klaassen review the Journal of Urology publication "Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report" led by Drs Surena Matin and Seth Lerner. |
|
|
|
|
|
|
|
|
 |
